The HARBOR trial was a dosing study which sought to determine the efficacy and safety of 2.0 mg and 0.5 mg doses of ranibizumab (anti-VEGF antibody) in treatment naive patients with choroidal neovascularization (CNV) secondary to AMD [13, 15]. Here, VEGFA is linked to age-related macular degeneration.